GEMSTONE Oncology logo
MenuClose

DNA Repair Deficiencies in Gynecologic Cancers: Implications for Therapeutic Targeting

  • DNA Repair Deficiencies in Gynecologic Cancers: Implications for Therapeutic Targeting - Slide Module
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide

Download Slide Module

DNA repair deficiency is the single most important therapeutic target for ovarian cancer and a smaller subset of endometrial and cervical cancers.

Michael J. Birrer, MD, PhD
The University of Alabama at Birmingham
GEMSTONE Committee Chair: Michael J. Birrer, MD, PhD

Aberrant DNA repair can lead to cancerous transformation. We now have agents that can leverage these defects to effectively treat gynecologic and other malignancies.

Thomas J. Herzog, MD
University of Cincinnati
GEMSTONE Committee Member: Thomas J. Herzog, MD

DNA repair deficiencies present an opportunity for therapeutic targeting in gynecologic cancers.

Cells have evolved a number of mechanisms to repair damaged DNA, and deficiencies in these pathways are common in gynecologic cancers.

Tumors with alterations in DNA repair pathways, particularly homologous recombination and mismatch repair, show increased sensitivity to some therapies, including PARP inhibitors and immune checkpoint inhibitors. Genetic testing and clinical features can help identify patients most likely to benefit from therapies that target DNA repair deficiencies.

Explore the module further to learn more about therapeutic targeting of DNA repair deficiencies in gynecologic cancers—or download the module for later review offline.